Group 1 - The core focus of the news is the explosive growth of the brain-computer interface (BCI) sector in the A-share market, with significant stock price increases observed on the first trading day of 2026, particularly for companies involved in BCI technology [1][5] - Notable stock performances include BeiYikang with a 30% increase, and other companies like Sanbo Brain Science, Xiangyu Medical, and Meihai Medical all achieving around 20% gains [1][5] - The surge in the BCI sector is attributed to three major developments: Neuralink's announcement of large-scale production of BCI devices, the implementation of new industry standards in China, and successful clinical trials demonstrating the technology's effectiveness [3][4][6] Group 2 - Neuralink, led by Elon Musk, announced that its BCI devices will enter mass production in 2026, along with a breakthrough in automated surgical technology for implanting devices [3] - A new industry standard for BCI medical devices in China, effective January 1, 2026, aims to provide regulatory clarity and facilitate clinical trials and product approvals [4] - A successful human trial in China demonstrated the ability to restore movement in paralyzed patients using implanted electrodes, showcasing rapid advancements in BCI technology [6] Group 3 - Investment interest in the BCI sector is heightened, with major international banks like Goldman Sachs, BNP Paribas, and Morgan Stanley focusing on companies like Innovation Medical, which has a strategic advantage due to its hospital resources [8] - The global BCI market is projected to reach $12.4 billion by 2034, with a compound annual growth rate of 17% from 2025 to 2034, indicating strong long-term growth potential [9] - The potential applications of BCI technology are expanding beyond medical uses, with possibilities in consumer electronics and smart home integration, suggesting a broader market impact [11] Group 4 - Despite the excitement, challenges remain in ensuring the long-term viability of implanted electrodes and improving the accuracy of non-invasive BCI systems [12] - Following the stock price surge, regulatory bodies have issued inquiries to several companies in the BCI sector to ensure transparency regarding their business operations and R&D progress [12] - Innovation Medical's stock has seen significant increases, but analysts caution that its current valuation is high, and investors should monitor the actual progress of its BCI projects and their impact on profitability [14]

Summary of Zhongke Information Conference Call Company Overview - **Company**: Zhongke Information - **Industry**: Brain-Computer Interface (BCI) and Medical Robotics Key Points Industry and Market Potential - The market potential for implanted brain-machine technology in anesthesia robots is estimated to be between **12 billion to 20 billion RMB** (approximately **$1.8 billion to $3 billion**) with a projected **30% penetration rate** [2][4] - The company plans to expand into rehabilitation and pain management sectors, currently conducting trials at the **Wan'an Rehabilitation Hospital** in Tianfu New District [2][4] Product Development and Clinical Trials - Zhongke Information's anesthesia robot has completed **15 clinical trials** successfully, with plans to complete **200 trials** to obtain a Class III medical device certification from the state [2][5] - The company expects to finish clinical trials and submit for certification by the end of this year, aiming for revenue generation by **the second half of 2027** [2][5] Technological Collaboration and Advancements - Collaboration with the **Suzhou Institute of Nano-Tech and Nano-Bionics** has improved the accuracy of EEG signal collection and decoding [3] - Despite being behind **Neuralink** in technology, Zhongke Information is leading in medical rehabilitation applications domestically [3] Revenue Model and Pricing - The expected price for each anesthesia robot is around **1 million RMB** (approximately **$150,000**) [5][7] - Currently, the company employs a unified pricing model for the anesthesia robot, with no established independent pricing standards for its use in rehabilitation hospitals [5][7] Future Directions and Strategic Plans - The company is optimistic about its future, especially with the large-scale production plans of **Neuralink** and the inclusion of brain-machine interfaces in the national **14th Five-Year Plan** [6] - Zhongke Information aims to leverage its advantages as a national technology team and integrate resources from the Chinese Academy of Sciences to achieve breakthroughs in practical applications of brain-like intelligent technology [6] Insurance and Reimbursement Considerations - There is currently no clear indication whether the anesthesia robot will be included in health insurance coverage, and the company is monitoring policy developments closely [7] Additional Important Information - All domestic brain-machine interface products are still in clinical trial phases, with no products having received formal certification yet, indicating that full commercialization will take time [2][4]

（文章来源：证券日报） 证券日报网讯 1月5日，中科信息发布公告称，公司于近日收到全资子公司成都中科信息技术有限责任 公司（简称"成都中科"）的通知，因经营发展的需要，成都中科对其经营范围进行了变更，并按照国家 现行的表述规范对公司经营范围表述进行了调整。目前已完成工商变更登记手续，并取得了四川天府新 区智慧城市运行局换发的《营业执照》，本次变更仅涉及经营范围变更，其他事项不变。 ...

证券代码：300678 证券简称：中科信息 公告编号：2026-001 中科院成都信息技术股份有限公司 关于全资子公司变更经营范围并完成工商登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 4.住 所：四川天府新区兴隆街道科智路 1369 号 5.法定代表人：史志明 6.注册资本：6000 万人民币 7.成立日期：2015 年 12 月 18 日 8.经营范围：一般项目：技术服务、技术开发、技术咨询、技术交 流、技术转让、技术推广；软件开发；软件外包服务；数据处理和存储 1 / 2 中科院成都信息技术股份有限公司（以下简称"公司"）于近日收 到全资子公司成都中科信息技术有限责任公司（以下简称"成都中科"） 的通知，因经营发展的需要，成都中科对其经营范围进行了变更，并按 照国家现行的表述规范对公司经营范围表述进行了调整。 目前已完成工商变更登记手续，并取得了四川天府新区智慧城市运 行局换发的《营业执照》，本次变更仅涉及经营范围变更，其他事项不 变。具体情况如下： 一、变更后的营业执照信息 1.公司统一社会信用代码：91510100MA61T0349K ...

Group 1 - The Shanghai Composite Index is at 4005.73 points, above the annual line, with an increase of 0.93% [1] - The total trading volume of A-shares today is 1,402.986 billion yuan [1] - A total of 154 A-shares have surpassed the annual line, with notable stocks showing significant deviation rates including Yingkang Life, Gangtong Medical, and Beilu Pharmaceutical at 10.63%, 10.61%, and 9.97% respectively [1] Group 2 - The top three stocks with the highest deviation rates from the annual line are: - Yingkang Life (12.85% increase, 10.63% deviation) - Gangtong Medical (11.91% increase, 10.61% deviation) - Beilu Pharmaceutical (10.20% increase, 9.97% deviation) [1] - Other notable stocks with significant increases include: - Guanhao Biological (14.87% increase, 8.29% deviation) - Baichu Electronics (6.95% increase, 6.79% deviation) [1] - Stocks with smaller deviation rates that have just crossed the annual line include *ST Yedao, Shiyan Institute, and Shanxi Securities [1]

每经AI快讯，1月5日，脑机接口概念盘中持续扩大涨幅，博拓生物、航天长峰（600855）封涨停，此 前倍益康、三博脑科（301293）、翔宇医疗、伟思医疗、诚益通（300430）等近20股涨停，冠昊生物 （300238）、狄耐克（300884）、中科信息（300678）、汉威科技（300007）、道氏技术（300409）等 多股涨超10%。 ...

Group 1 - The company emphasizes its commitment to information and cybersecurity issues, indicating a proactive approach to these challenges [2] - The products and solutions offered by the company across various industries incorporate effective offensive and defensive technologies, as well as emergency mechanisms [2]

Core Viewpoint - Zhongke Information's stock price has shown volatility, with a year-to-date decline of 16.69% but a recent increase of 2.93% over the last five trading days, indicating potential recovery signals in the market [1]. Group 1: Stock Performance - As of December 24, Zhongke Information's stock price is 30.26 CNY per share, with a market capitalization of 8.969 billion CNY [1]. - The stock has experienced a trading volume of 78.7984 million CNY, with a turnover rate of 0.90% [1]. - The company has seen a net inflow of main funds amounting to 1.2402 million CNY, with large orders accounting for 16.25% of total purchases [1]. Group 2: Financial Performance - For the period from January to September 2025, Zhongke Information reported a revenue of 194 million CNY, reflecting a year-on-year decrease of 11.22% [2]. - The net profit attributable to shareholders for the same period was 4.5133 million CNY, down 27.07% year-on-year [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Zhongke Information is 48,900, a decrease of 16.28% from the previous period [2]. - The average number of tradable shares per shareholder has increased by 19.34% to 5,945 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 1.6567 million shares to 2.9402 million shares [3].

格隆汇12月23日丨中科信息(300678.SZ)在投资者互动平台表示，公司未开展手机相关业务。 ...

Capital Operations - Shen Cheng Jiao plans to raise no more than 1.8 billion yuan through a private placement for the research and large-scale application of low-altitude and autonomous driving intelligent transportation equipment and related projects [2] - Ding Gu Ji Chuang's invested company Hang Ju Technology has developed the WS series flexible reusable thermal protection materials, which have been applied to the Blue Arrow Aerospace Zhuque-3 rocket body [2] - Zhen You Technology has ongoing ground core network development projects in both high-orbit and low-orbit satellite communication fields [2] Investment and Operations - Zhongjin Company plans a stock swap merger with Dongxing Securities and Xinda Securities, with stock trading resuming on December 18 [1] - Beiqi Blue Valley aims to continue developing L3 models in the mid-to-high-end brand segment, with some L3 model products currently in the development stage [1] - Xingmin Zhitong's communication domain controller is currently being used in L3 and L4 autonomous vehicles, including Robotaxi and unmanned logistics vehicles [1] Contracts and Collaborations - Pudong Construction's subsidiary recently won contracts totaling 1.649 billion yuan [1] - China Duty Free Group's wholly-owned subsidiary signed a contract for the transfer of duty-free store project operating rights, planning to invest 102 million yuan to establish a joint venture with Shanghai Airport [1] - Shanghai Airport signed a contract with Dufry and China Duty Free Group for the transfer of duty-free store project operating rights, with Dayang Shanghai not renewing the contract [1] - China CRRC and its subsidiaries recently signed contracts totaling 53.31 billion yuan, with wind power and energy storage equipment sales contracts amounting to approximately 16.65 billion yuan [1] Performance - China Nuclear Construction reported a cumulative operating income of 92.03 billion yuan by November 2025 [4] Share Buybacks - Shibao Testing's executives plan to increase their holdings of company shares by 8 million to 12 million yuan [4]